Faruqi and Faruqui, LLP Logo
Share this page

News & Events

Page 1 of 6 (120 Items)
24
Feb
2017

Faruqi & Faruqi obtains Collective Certification on behalf of Aldi Store Managers

On February 22, 2017, the Honorable Andrew Baxter of the United States District Court for the Northern District of New York conditionally certified a collective action brought by Aldi Store Managers alleging the grocery chain misclassified them as exempt employees under the FLSA, in Griffin et al. v. Aldi... READ MORE

23
Feb
2017

Court Grants Class Certification to Direct Purchasers of Lidoderm in Antitrust Case and Appoints Faruqi & Faruqi Co-Lead Counsel

On February 21, 2017, the Honorable William H. Orrick of the United States District Court for the Northern District of California certified a class of direct purchasers of the pain medication patch Lidoderm in the antitrust case In re Lidoderm Antitrust Litigation, No. 3:14-md-02521-WHO.  Judge Orrick further appointed Faruqi... READ MORE

10
Feb
2017

Court Grants Final Approval of Settlement in In re Dynavax Technologies Corporation Securities Litigation

On February 6, 2017, the Honorable Charles R. Breyer, United States District Judge for the Northern District of California, entered final approval of the settlement reached in In re Dynavax Technologies Corp. Sec. Litig., No: 3:13-CV-02796-CRB, for which Faruqi & Faruqi, LLP served as sole Lead Counsel on behalf... READ MORE

7
Feb
2017

COURT APPOINTS FARUQI & FARUQI, LLP LEAD COUNSEL IN SECURITIES CLASS ACTION AGAINST GOPRO, INC.

On February 6, 2017, Senior District Judge Claudia Wilken of the United States District Court for the Northern District of California appointed Faruqi & Faruqi, LLP to serve as Lead Counsel in Bielousov v. GoPro, Inc., et al., No. 4:16-CV-06654-CW. For further inquiries regarding this matter, please contact... READ MORE

3
Feb
2017

F&F Wins Significant Appeal against Verizon Communications, Inc.

The New York Appellate Division, First Department, reversed a lower court’s rejection of the settlement for equitable relief in Gordon v. Verizon, 2017 NY Slip Op 00742 (1st Dep’t February 2, 2017)  holding that settlements for additional internal corporate information and governance reforms continue to serve as “a useful... READ MORE

23
Jan
2017

James (Josh) M. Wilson and Adam Steinfeld made partners with the Firm

Faruqi & Faruqi is pleased to announce that Josh Wilson and Adam Steinfeld are now partners with the Firm.  Josh continues to litigate in securities matters on behalf of investors nationwide. Adam continues to practice in the area of antitrust litigation. Congratulations Josh and... READ MORE

19
Jan
2017

Peter Kohn and Joseph T. Lukens were both honored with the designation of Super Lawyer for 2017

Peter Kohn and Joseph T. Lukens, Partners of Faruqi & Faruqi, LLP, were both honored with the designation of Super Lawyer in Pennsylvania for the year 2017. Super Lawyers is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high-degree of peer... READ MORE

12
Jan
2017

Faruqi Firm Files Antitrust Case Over ADHD Medication

On January 11, 2017, Faruqi & Faruqi, LLP filed a federal antitrust class action case against brand and generic manufacturers of ADHD drug, Intuniv.  The complaint alleges that the companies, Shire and Actavis, violated the antitrust laws by entering into an anticompetitive agreement that delayed generic competition for Intuniv. ... READ MORE

9
Jan
2017

Faruqi & Faruqi files slack-fill case against Nestle’ U.S.A., Inc.

On January 3, 2017, Faruqi & Faruqi, LLP filed a federal consumer class action case against Nestle’ U.S.A., Inc. for allegedly under-filling its opaque theater box Raisinets products to the detriment of unsuspecting consumers. The case was filed in the United States District Court for the Central District of... READ MORE

6
Jan
2017

Faruqi & Faruqi files cases against generic drug manufacturers

On December 27 & 28, 2016, Faruqi & Faruqi, LLP filed several cases against generic drug manufacturers for allegedly conspiring to raise the prices of generic divalproex ER, desonide, pravastatin, econazole, fluocinonide, levothyroxine, propranolol, and clobetasol. The firm represents classes of direct purchasers of the generic drugs and is... READ MORE

16
Dec
2016

Faruqi & Faruqi, LLP announces preliminary approval of settlement in In re Dynavax Technologies Corporation Securities Litigation

Faruqi & Faruqi LLP is pleased to announce that the Court has preliminarily approved a settlement in In re Dynavax Technologies Corp. Sec. Litig., Case No: 3:13-CV-02796-CRB.  The settlement provides for a cash payment of $4.5 million in exchange for plaintiffs’ release of all claims alleged in the action. ... READ MORE

2
Nov
2016

Faruqi & Faruqi, co-Lead Counsel, Obtains a Significant Victory on Behalf of Investors Against Comverge Inc.’s Former Board of Directors

On October 31, 2016, the Honorable Tamika Montgomery-Reeves, Vice Chancellor of the Delaware Court of Chancery, denied a motion for summary judgment filed by the former board of directors (the “Board”) of Comverge Inc. (“Comverge”).  In denying summary judgment, the Court found that there were material facts in dispute... READ MORE

13
Oct
2016

Faruqi & Faruqi, Lead Counsel, Obtains Final Approval of $3,000,000 Common Fund in In re Mavenir Systems, Inc. Stockholders Litigation

On October 12, 2016, the Honorable Tamika Montgomery-Reeves, Vice Chancellor of the Delaware Court of Chancery, granted final approval of the proposed settlement in In re Mavenir Systems, Inc. Stockholders Litigation, C.A. No. 10757-VCMR.  Faruqi & Faruqi, as lead counsel (“Lead Plaintiff”), obtained significant benefits to stockholders discussed below.... READ MORE

28
Sep
2016

Faruqi & Faruqi Challenges Conflicted Merge Healthcare, Inc., Transaction

On September 27, 2016, Faruqi & Faruqi, LLP (“Faruqi”) presented a significant motion to dismiss argument before Vice Chancellor Glasscock in a case challenging IBM’s $1 billion acquisition of Merge Healthcare Inc. (“Merge”).  Derrick Farrell, a partner at Faruqi, argued that the transaction was mired with conflicts and meant... READ MORE

21
Sep
2016

Court Grants Final Approval of Settlement in Chelsea Therapeutics International, Ltd. Securities Litigation

The Honorable Max O. Cogburn, Jr., United States District Judge for the Western District of North Carolina entered final approval of the settlement reached in McIntyre v. Chelsea Therapeutics International, Ltd., et al., No. 3:12-CV-00213-MOC-DCK (W.D.N.C.) for which Faruqi & Faruqi, LLP served as sole Lead Counsel on behalf... READ MORE

20
Sep
2016

Faruqi & Faruqi, LLP Obtains Significant Victory On Behalf Of Investors Against ACADIA Pharmaceuticals Inc.

On September 19, 2016, United States District Judge Barry Ted Moskowitz denied a motion to dismiss filed by ACADIA Pharmaceuticals Inc. (“ACADIA”), former Chief Executive Officer (“CEO”) Uli Hacksell, current President and CEO Stephen R. Davis, and former Chief Medical Officer and Executive Vice President, Development Roger G. Mills... READ MORE

19
Aug
2016

We are proud to announce the appointment of Timothy J. Peter to partner. Mr. Peter will head up the firm's Consumer Protection Litigation Department.

Timothy Peter joined Faruqi & Faruqi in 2015. Prior to joining Faruqi & Faruqi, Mr. Peter was an associate at Cohen Placittella & Roth, P.C. where he was involved in such high profile litigation as: In re Vioxx Products Liability Litigation ($8.25 million recovery for the Commonwealth of Pennsylvania)... READ MORE

13
Jun
2016

Faruqi & Faruqi, LLP announces appointment as co-lead counsel and preliminary approval of settlement in In re Boulder Brands, Inc. Stockholder Litigation

Faruqi & Faruqi LLP is pleased to announce its appointment as co-lead counsel and preliminary approval of a settlement in In re Boulder Brands, Inc. Stockholder Litigation, Lead Case No: 2015-CV-01349 (consolidated with Case No. 2015-CV-31474). The settlement involves supplemental disclosures in SEC filed documents in connection with the... READ MORE

1
Jun
2016

Faruqi & Faruqi, LLP Announces Preliminary Court Approval of Settlement in McIntyre v. Chelsea Therapeutics International, Ltd., et al.

Faruqi & Faruqi LLP is pleased to announce the Court’s preliminary approval of a settlement in MacIntyre v. Chelsea Therapeutics International, Ltd., et al., Case No. 3:12-CV-213-MOC-DCK (W.D.N.C.).  The settlement provides for $5,500,000 in cash to be paid to class members who purchased or otherwise acquired Chelsea common stock... READ MORE

13
May
2016

Court Appoints Faruqi & Faruqi, LLP Lead Counsel in Securities Class Action Against Xoma Corporation.

On May 13, 2016, District Court Judge Haywood S. Gilliam, Jr. of the United States District Court for the Northern District of California appointed Faruqi & Faruqi, LLP to serve as Lead Counsel in Markette v. Xoma Corporation, et al., Case No. 15-cv-03425-HSG. For further inquiries... READ MORE

Page 1 of 6 (120 Items)